Regeneron Claims Biocon Drug Mimics Its Patented Medicine

By Ronan Barnard ( November 28, 2025, 6:24 PM GMT) -- Regeneron Pharmaceuticals has countersued Biocon to block it from infringing on its patents upholding its medication to treat macular degeneration, denying that the Indian pharmaceutical group's formulation would not infringe on its intellectual property in the U.K....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login